NCT00041574View on ClinicalTrials.gov

Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions
Pulmonary HypertensionLung DiseaseSickle Cell DiseaseCardiac TransplantLung Transplant
Interventions
DRUG

Inhaled Nitric Oxide

Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).

Trial Locations (3)

80262

The Children's Hospital, Denver

University of Colorado Hospital, Denver

02903

Rhode Island Hospital, Providence

Sponsors

Lead Sponsor

Mallinckrodt
All Listed Sponsors
lead

Mallinckrodt

INDUSTRY